Independent health institutes in Switzerland and Belgium reported the following results from a preliminary trial of COVID-RAPID:
Percentage of People Testing Positive with COVID-RAPID test
| Days Symptomatic | Belgium (1) | Switzerland (2) |
| Covid-19 Day 0 – 6 | 28% | 20% |
| Covid-19 Day 7 – 11 | 62% | 60% |
| Covid-19 Day 12+ | 100% | 95% |
| Sensitivity | 60% | 90% |
| Specificity | 97% | 100% |
This means that our test catches an average of 97.5% of cases after day 12 of infection. To API’s knowledge, Covid-Rapid is the only serology test on the market that has any significant data to support its accuracy.
Citations
(1) Dr. Pieter Vermeersch, PhD. Laboratory of Clinical Bacteriology and Mycology, University of Leuven, National Reference Center for Respiratory Pathogens.
(2) Patrice Nordmann , MD PhD. Professor and Chair of Microbiology, Head Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology Department of Medicine, Faculty of Science and Medicine; Director INSERM European Laboratory (French National Institute for Health and Medical Research), Director National Reference Center for Emerging Antibiotic Resistance (Switzerland), University of Fribourg, Fribourg and Institute for Microbiology, University of Lausanne, University hospital Center, Lausanne, Switzerland
